ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
Presentation of Q1 2024 Results
Tromsø, Norway, May 8th, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.0 million and an EBITDA of NOK 2.3 million for the first quarter of 2024.
Joint Research with Austrian Centre of Industrial Biotechnology
Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the Austrian Centre of Industrial Biotechnology (acib) enter a joint research project to uncover the benefits of salt active nucleases in the purification of bionanoparticles (BNP’s).
Research Paper on ArcticZymes R2D Ligase Published in the Biotechnology Journal
Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase™ is published in the Biotechnology Journal
ArcticZymes Technologies ASA Q4 2023 Results & Presentation
Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.